Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.
The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.
Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 17, 23 | 0.00 Decreased by N/A% | - |
| Sep 7, 23 | -0.02 Increased by +85.64% | -0.02 |
| May 31, 23 | 0.00 Decreased by -100.00% | - |
| Mar 28, 23 | -0.02 Increased by +91.61% | - |
| Aug 11, 21 | 0.00 Increased by +100.00% | -0.14 Increased by +100.00% |
| Jun 2, 21 | -0.14 Increased by +95.75% | -0.14 |
| Mar 31, 21 | 0.08 Increased by +102.56% | - |
| Dec 31, 20 | -0.24 Increased by +59.35% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 361.10 K Decreased by -89.87% | -6.05 M Decreased by -9.64% | Decreased by -1.67 K% Decreased by -982.12% |
| Sep 30, 23 | 533.43 K Decreased by -20.97% | -6.56 M Increased by +73.58% | Decreased by -1.23 K% Increased by +66.57% |
| Jun 30, 23 | 8.79 M Increased by +N/A% | -13.60 M Decreased by N/A% | Decreased by -154.74% - |
| Mar 31, 23 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Dec 31, 22 | 3.56 M Increased by +N/A% | -5.51 M Decreased by N/A% | Decreased by -154.74% - |
| Sep 30, 22 | 674.99 K Increased by +N/A% | -24.83 M Decreased by N/A% | Decreased by -3.68 K% - |
| Jun 30, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Mar 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |